secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001140361-25-039656
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech requests FDA meeting to discuss expedited approval for PDS0101 in HPV16+ HNSCC
--------------------------------------------------------------------------------

- Final VERSATILE-002 data: median PFS 6.3 months, median OS 39.3 months in recurrent/metastatic HPV16+ HNSCC.
- Proposes amending Phase 3 VERSATILE-003 trial to add PFS as earlier primary endpoint for potential accelerated approval.
- VERSATILE-003 temporarily paused during FDA review; currently enrolled patients continue treatment.
- FDA meeting requested to expedite regulatory pathway based on strong survival results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125039656/0001140361-25-039656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125039656/ef20057871_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-039656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer